3 days Ago By ABMN Staff
CareDx ( NASDAQ:CDNA – Get Free Report ) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday. A number of other equities analysts have also recently issued reports on the stock.
Craig Hallum boosted their price objective on shares of CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, August 1st.
The Goldman Sachs Group lifted their price target on shares of CareDx from $16.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, August 1st.
BTIG Research raised CareDx from a “neutral” rating to a “buy” rating and set a $40.00 target price on the stock in a research note on Monday, August 19th. HC Wainwright restated a “neutral” rating on shares of CareDx in a report on Thursday, August 1st.
Finally, Wells Fargo & Company assumed coverage on shares of CareDx in a research note on Tuesday, August 27th. They issued an “underweight” rating and a $28.00 price target for the company.
One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.
80. Check Out Our Latest Report on CareDx CareDx Price Performance CareDx ( NASDAQ:CDNA – Get Free Report ) last announced its earnings results on Wednesday, July 31st. The company reported ($0.
03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37.
CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%.
The business had revenue of $92.27 million for the quarter, compared to the consensus estimate of $67.20 million.
Sell-side analysts expect that CareDx will post -0.84 earnings per share for the current fiscal year. Insider Activity In other news, insider Alexander L.
Johnson sold 21,557 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total value of $702,327.
06. Following the sale, the insider now directly owns 284,983 shares of the company’s stock, valued at approximately $9,284,746.14.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . In other news, insider Alexander L. Johnson sold 34,231 shares of the company’s stock in a transaction that occurred on Monday, August 19th.
The shares were sold at an average price of $33.55, for a total value of $1,148,450.05.
Following the transaction, the insider now directly owns 284,983 shares in the company, valued at approximately $9,561,179.65. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink .
Also, insider Alexander L. Johnson sold 21,557 shares of the stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.
58, for a total value of $702,327.06. Following the completion of the sale, the insider now owns 284,983 shares in the company, valued at $9,284,746.
14. The disclosure for this sale can be found here . Insiders have sold a total of 91,340 shares of company stock worth $3,025,415 over the last 90 days.
4.20% of the stock is currently owned by corporate insiders. Institutional Inflows and Outflows Several hedge funds and other institutional investors have recently modified their holdings of CDNA.
ClariVest Asset Management LLC increased its holdings in shares of CareDx by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 64,027 shares of the company’s stock valued at $994,000 after purchasing an additional 1,810 shares in the last quarter.
BNP Paribas Financial Markets raised its position in shares of CareDx by 2.1% in the fourth quarter. BNP Paribas Financial Markets now owns 90,258 shares of the company’s stock valued at $1,083,000 after buying an additional 1,876 shares during the last quarter.
GAMMA Investing LLC lifted its stake in shares of CareDx by 1,021.8% during the 2nd quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after purchasing an additional 2,013 shares during the period.
Price T Rowe Associates Inc. MD boosted its stake in CareDx by 8.7% in the 1st quarter.
Price T Rowe Associates Inc. MD now owns 29,396 shares of the company’s stock worth $312,000 after buying an additional 2,344 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of CareDx by 13.
4% in the second quarter. Allspring Global Investments Holdings LLC now owns 21,164 shares of the company’s stock worth $329,000 after acquiring an additional 2,503 shares during the last quarter. CareDx Company Profile ( Get Free Report ) CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Further Reading Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter .
.
